Katy K. Tsai - Concepedia

Author

Katy K. Tsai

University of California, San Francisco

Also Known As

Embree, Genevieve, K. Tsai, K.K. Tsai, Katy K Tsai, Katy K. Tsai, Katy Tsai

184

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco UCSF Helen Diller Family Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center University of California, Los Angeles The University of Texas MD Anderson Cancer Center

About

Katy K. Tsai is an author at University of California, San Francisco specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	1.3K
2	Immunology	11	11	1.2K
3	Health Sciences	4	4	60
4	Cell Biology	2	2	256
5	Diagnostic Sciences	1	1	100

Katy K. Tsai

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Annals of Oncology Autoimmune DisordersAutoimmune DiseaseAnti-pd-1 TherapyMelanomaImmunology	2016	811
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Paul C. Tumeh, Matthew D. Hellmann, Omid Hamid, Cancer Immunology Research	2017	543
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma Adil Daud, Kimberly Loo, Mariela Pauli, Journal of Clinical Investigation	2016	515
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies Alain P. Algazi, Katy K. Tsai, Alexander N. Shoushtari, Cancer	2016	362
The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma Alexander N. Shoushtari, Rodrigo Ramella Munhoz, Deborah Kuk, Cancer	2016	298
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma Alain P. Algazi, Chris Twitty, Katy K. Tsai, Clinical Cancer Research	2020	139
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade Chien-Chun Steven Pai, John Huang, Xiaoqing Lu, Immunity Tumor-specific T CellsTumor ImmunologyCancer ImmunosurveillanceClonal DeletionImmunology	2019	134
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy Adi Nosrati, Katy K. Tsai, Simone M. Goldinger, British Journal of Cancer	2017	128
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients Alain P. Algazi, Shailender Bhatia, Sanjiv S. Agarwala, Annals of Oncology	2020	125
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment Kristen E. Pauken, Osmaan Shahid, Kaitlyn A. Lagattuta, The Journal of Experimental Medicine T-regulatory CellImmunologyPathologyImmunophenotypingImmunotherapy	2020	122

Page 1